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Obesity is an extremely common condition in the Western world, affecting approximately one-third of the population. The cost of treatment of the medical consequences of obesity accounts for a large proportion of the health care budget. It is not surprising, therefore, that the discovery of the`fat busting' hormone leptin has aroused extensive scienti®c interest and media coverage over the last few years. Since the discovery of leptin in 1994, no fewer than 3000 scienti®c papers, many newspaper articles, much television coverage and a deluge of information on the Internet have appeared. Despite this there is surprisingly little detailed information available to clinical biochemists on leptin measurements and their clinical utility in health and disease.
It has been known since the 1970s 1 that single gene mutations in obese (ob/ob) and diabetic (db/db) mice led to gross obesity. It was not until 1994, however, that the pioneering work of Friedman et al. 2 showed that the ob gene product, a 16 kDa protein named leptin (from the Greek leptos, meaning thin), was produced by the adipocyte. Mutations in the ob gene led to an absence of circulating leptin in the ob mouse, and resulting hyperphagia and gross obesity in such animals could be completely reversed by administration of leptin. A few years later it was discovered that the abnormality in db/db mice was severe leptin resistance caused by a leptin receptor mutation. 3, 4 From these studies it is clear (in mice at least) that leptin is intimately involved in controlling adiposity, and further work has led to the hypothesis that leptin carries information about the size of the body's energy store to the brain. The hypothalamus then responds via neuropeptide-Y to adjust food intake and metabolic rate accordingly (see Fig. 1a ). The idea that leptin administration might reduce adiposity resulted in a multi-million dollar investment by the Amgen Corporation in the USA to ®nd a`cure' for human obesity.
Unfortunately, in the majority of cases of human obesity there is no evidence of a monogenic defect in leptin homeostasis. Rather than low circulating leptin concentrations, as found in the obese ob/ob mouse, obese humans have leptin concentrations which are increased in proportion to their fat mass. 5 Given the obvious failure of these high leptin concentrations to produce changes in energy intake or expenditure to restore fat mass to normal, it has been proposed that human obesity is a leptin`resistant' state (see Fig. 1b ). This explanation, however, has been criticized by some, 6 since the only evidence for leptin resistance is that obese humans generally have higher circulating leptin concentrations than do lean subjects. In 1996, the human equivalent of the ob/ob mouse gene was discovered, providing direct evidence that leptin was important in the control of fat mass in the human. Montague and co-workers 7 identi®ed a mutation in two children in the same consanguineous pedigree. Both sisters were grossly obese and serum leptin concentrations were extremely low. Interestingly, administration of human recombinant leptin to the older sister increased satiety and rapid weight decrease occurred. 8 The human equivalent of the db/db mouse gene has also been discovered, 9 but it appears that genetic mutations are an extremely rare cause of obesity in humans.
It is now recognized that leptin is involved in a wide range of functions. As well as inhibiting food intake, leptin stimulates and maintains energy expenditure, is a signal to the reproductive system, is involved in haemopoiesis and the immune response and acts as a`metabolic' hormone in a wide range of processes. 10 The aim of this short article is to familiarize the reader with the rapidly expanding information on leptin, describe the measurement of circulating concentrations of leptin and the leptin binding component and brie¯y review the value, or potential value, of such measurements in human disease. A deeper coverage of leptin may be found in a number of excellent recent reviews. 10±14
BIOCHEMICAL CHARACTERISTICS OF LEPTIN AND LEPTIN BINDING
Leptin is a highly hydrophobic 16 kDa protein composed of 167 amino acids and is a member of the cytokine family. Structural analysis reveals a four-a-helix bundle structure with a three-dimensional fold held together by a disulphide link between Cys(96) and Cys (146). 15, 16 There is evidence that the N-terminal region is essential for both biological and receptor binding activities and that the Cterminal loop structure is also important in enhancing these actions. 17 As predicted from the gene sequence, the amino acid sequences in humans and mice share 84% homology and have features of a secreted protein. The human leptin gene is on chromosome 7q31. Positional cloning was used to identify the ob gene in mice. 2 The ob gene encodes a 4.5-kilobase adipose tissue messenger RNA with a highly conserved 167-amino acid open reading frame Leptin and leptin binding 245 and a 21-amino acid secretory signal sequence. This sequence appears to be unique, with no homologues in any of the published sequence data bases. The coding sequence is contained in two exons and three introns. Apart from containing all the necessary elements to support basal transcription, the 59¯anking region of the leptin gene contains dozens of putative binding sites for transcription factors such as the cAMP response element and a glucocorticoid response element. 18 To date the leptin gene has been found to be expressed only in white adipose tissue 19 and placenta. 20, 21 Congenital leptin de®ciency in the human has been shown to be due to either a homozygous frame-shift mutation 7 or a C to T substitution 22 (see Table 1 ). Leptin, like other members of the cytokine family, exerts its effect through cell surface receptors to stimulate the Janus kinase-STAT transcription factor pathway. 11 In the ob/ob mouse, a nonsense mutation at codon 105 results in the synthesis of a truncated protein which is not secreted by the adipocyte and not detectable in mouse plasma. Several alternatively spliced isoforms of the leptin receptor have been identi®ed (Ob-Ra, Ob-Rb, Ob-Rc, Ob-Rd and Ob-Re). One or more splice variants are expressed in most (if not all) tissues, indicating that leptin has a range of targets consistent with the growing evidence that it has multiple functions. 10 Ob-Ra is thought to be a leptin transporter. Ob-Rb is a long form containing an intracellular signalling domain and is strongly expressed in the hypothalamus, a key target for leptin. This long form is similar to the glycoprotein gp130, the common signal transducing subunit of a group of cytokine receptors. 11 It is the Ob-Rb transcript that is mutant in db/db mice, with abnormal splicing causing a mutant protein that is truncated and is defective in signal transduction. 4 Ob-Re is a soluble form of the transmembrane leptin receptor. 23 Recently, a mutation has been detected in the human leptin receptor gene that results in a truncated leptin receptor lacking both the transmembrane and the intracellular domains 9 (see Table 1 ).
Circulating binding proteins have been described for many hormones, growth factors and cytokines. In many instances, such binding proteins have a physiological function and may alter clearance, control bioavailability and offer protection against degradation. It is therefore not surprising that leptin is bound to proteins in the circulation but the function of such binding is as yet unclear.
The soluble leptin receptor (Ob-Re; approximately 90 kDa) has been shown to be capable of binding leptin in a 1 : 1 ratio 23 and may account for about 10% of leptin binding in the circulation. 24 These workers also identi®ed a 280 kDa protein as a putative leptin binding protein.
Houseknecht and co-workers 25 described binding components in human serum with molecular masses of 176 and 240 kDa. A high molecular mass component (450 kDa) of unknown identity has been shown to competitively bind leptin in human serum. 26 Recently, it has been demonstrated that an even larger protein, the oxidized form of a 2 -macroglobulin (750 kDa), can bind leptin competitively. 27 Due to leptin's hydrophobic nature it is prone to aggregation, and it is possible that some of this published information could be accounted for by aggregation of the radiolabelled leptin used in the binding studies. Leptin binding in the circulation is high-af®nity binding with a dissociation constant (K d ) in the region of 1 nmol/L 24, 28, 29 and there is no evidence for binding to albumin or lipid. 29 
LEPTIN IMMUNOASSAYS
Sample collection and stability
Leptin in serum, plasma or cerebrospinal¯uid is stable over at least ®ve freeze/thaw cycles. We have observed no alteration in measured leptin concentrations in samples stored at 3 20 Ê C over a 2-year period. Samples are stable for at least 2 months when stored at 4 Ê C. 30, 31 In most radioimmunoassays (RIAs) similar results are obtained for serum, EDTA-plasma and heparinplasma samples, although this should be con-®rmed in all new assays.
Summary of available methods
Following the discovery of leptin, methods for measuring circulating concentrations in the human were rapidly developed. The ®rst assays were semi-quantitative, based on the immunoprecipitation/Western blotting technique using an immunopuri®ed biotinylated primary antibody raised by immunizing rabbits with a peptide corresponding to the ®rst 20 amino-terminal amino acids of leptin. 32 The need for more quantitative procedures was immediately apparent, and rapid and precise immunoassays were developed. The ®rst commercial assay was produced by Linco Research Inc (see Appendix for details) as described by Ma and co-workers. 30 This assay has been used for leptin measurements in more than 80% of the current published research on circulating leptin concentrations in humans and much of the information obtained using this kit has now been con®rmed by both other commercial and`in house' assays. The Linco assay utilizes [ 125 I]-labelled human recombinant leptin, human recombinant calibrators and an antiserum raised by immunizing rabbits with highly puri®ed recombinant human leptin. This RIA can be used to determine leptin concentrations in serum, plasma or tissue culture media. In addition Linco have developed a more sensitive leptin RIA suitable for measurement of leptin in¯uids such as cerebrospinal¯uid, which contain much lower leptin concentrations than those found in serum. 33 Assays for measuring rat, mouse and primate leptin are also available from Linco. A sensitive RIA for human leptin is available from Diagnostic Systems Laboratories (DSL: see Appendix). This company has also recently made available a coated tube immunoradiometric assay (IRMA) with a quoted sensitivity of 0´1 mg/L. Enzyme-linked immunosorbent assay (ELISA) procedures are now also commercially available (DRG Instruments GmbH, R+D Systems Ltd, DSL; see Appendix). In house' immunoassays have been developed using either monoclonal 34 or polyclonal antisera 5, 31, 35, 36 raised against either human recombinant leptin 5, 36, 37 or fragments of the molecule. 31, 35 There is little evidence of interferences in leptin immunoassays. Leptin appears to be a unique protein with no known circulating interfering immunoassay cross-reactants. Apart from human growth hormone and interleukin 6, which, like leptin, have a four helix bundle structure, most other substances used in cross-reaction studies appear to have been selected on the basis of associated function rather than structure i.e. insulin, proinsulin, C-peptide, insulin-like growth factor 1 (IGF-1) and glucagon. Although there is evidence that a proportion of leptin in the circulation is protein-bound, most (but not all ± see below) leptin immunoassays have been shown to measure total leptin. Immunoassay protocols do not include an agent for displacing endogenous binding components, implying that the af®nity of antibodies for leptin exceeds that of endogenous binding components. The sensitivity of most immunoassays (between 0´5 and 1 mg/L) is suitable for measuring circulating concentrations in most clinical situations.
Calibration
The matrix used for preparation of calibrants is either human serum, from which leptin has been removed by charcoal adsorption, 34 or animal serum 37 containing a form of leptin that does not cross-react with human leptin. Highly puri®ed human recombinant leptin is the material of choice for preparation of calibrants and is available commercially (Research Diagnostics Inc; see Appendix). All the standard procedures for radiolabelling proteins have been applied to leptin: chloramine-T, 36 lactoperoxidase, 37 Bolton and Hunter reagent 5 and iodogen. 31, 35 In my experience, the hydrophobic nature of the molecule can cause both aggregation and losses due to adsorption to glass or plastic reagent vessels. For this reason it is important that detergent (Triton-X100, 0´05%) is present at all times but especially during radioiodination and subsequent puri®cation. In addition, high concentrations of bovine serum albumin (1±2%) are usually included after iodination for stabilization.
Quality assurance
Since current procedures have essentially been designed for research purposes, leptin measurements have none of the sophistication of the established hormone assays familiar to clinical chemists. For example, as far as I am aware, there is no suitable commercial quality control material apart from that included in commercial kits, no external quality control programme and no certi®ed reference material. If leptin measurement is found to have a signi®cant clinical role, these de®ciencies will need to be addressed. In our own studies quality control serum samples containing a range of leptin concentrations are obtained by pooling samples from volunteers of variable body compositions, aliquots being stored at 3 20 Ê C before use.
Pre-analytical factors affecting interpretation
There are a number of factors that should be taken into consideration when interpreting leptin results. Although mutations of the ob and ob-receptor genes result in grossly abnormal concentrations of leptin and/or leptin binding and are, therefore, unlikely to pose an interpretative problem (see Table 1 ), identi®cation of minor abnormalities or interpretation of research ®ndings may be more dif®cult. Most studies relate results to body mass index (BMI) or fat mass. If BMI is used it is important to relate results to sex-matched reference ranges since it is well documented that, for a given BMI, women have leptin concentrations approximately twice that of men, 30 a difference that remains even after correction for percentage body fat. 38 Testosterone is believed to be partly responsible for this gender difference in adults 38 and the difference becomes apparent during puberty 39 as circulating testosterone concentrations increase. In addition, it is known that administration of testosterone to normal 40 and hypogonadal 41 men decreases circulating leptin concentrations. Thus, it is necessary to know the pubertal status of the patient and whether or not they are receiving testosterone. There are reports that circulating leptin concentrations in women increase during the luteal phase of the menstrual cycle. 42, 43 Leptin secretion is pulsatile and has a well documented diurnal rhythm. The peak leptin concentration occurs between 00:00 and 04:00 h and is approximately 30±40% higher than the nadir occurring between 08:00 and 12:00 h. 44, 45 It is therefore important that sample timing is standardized. There is little information on intra-individual variation over a prolonged period, but Ma and co-workers 30 have reported considerable variability, of the order of 30%, in two subjects in whom leptin was measured on eight successive mornings. These ®ndings merit more detailed investigation and, if con®rmed, indicate that modest intra-individual differences should be interpreted with caution even when samples are collected at the same time of day. Although normal feeding does not signi®cantly affect circulating leptin concentrations and nonfasting samples are acceptable, sudden and extreme alterations of feeding patterns should be avoided. Within 24 h of fasting, leptin concentrations decline to about 30% of initial basal values. Massive overfeeding over a 12-h period increases leptin concentrations by about 50% of initial basal values. 13
DETERMINATION OF LEPTIN BINDING IN THE CIRCULATION
Several procedures have been developed to assess the binding of leptin to higher molecular weight components in the circulation. The majority of methods rely on binding activity rather than measuring the mass of a speci®c macromolecule. Such procedures require preincubation of the sample with radio-labelled leptin, usually overnight at 4 Ê C, followed by separation of bound and free components in a number of ways: gel-®ltration, 24, 26, 27 sucrose gradient centrifugation, 25 spun column gel ®ltration 46 and charcoal adsorption. 29 Most of these methods probably measure binding of leptin to a mixture of macromolecules. Gel ®ltration 27 is tedious and time-consuming, but we have found that it does produce highly reproducible results and is a useful reference procedure. An example of elution pro®les using gel ®ltration is shown in Fig. 2 and illustrates differences in binding between an obese and a lean individual. A number of different types of gel have been used: Sephadex G-100 24, 27 and G-200, 24 Superdex 200 27 (Pharmacia, Uppsala, Sweden) and Ultragel ACA 44 26 (IBF Biotechnics, Columbia MD, USA). The amount of measured binding is lower if spun-columns incorporating Sephacryl S-200 HR (Pharmacia) are used for separation but the values are reported to correlate well with the gel ®ltration method. 46 A different innovative approach has been used by Horn and Lewandowski. 31, 47 While developing an RIA for leptin using antibodies raised againsta C-terminal leptin fragment(leptin 126±140 ), they obtained lower results than were obtained by the Linco kit procedure. Although the signi®cance of this ®nding was not immediately apparent, it later became clear that this antibody recognized only free leptin. 47 Expanding their repertoire, these workers raised antisera against an N-terminal fragment of leptin (leptin 26±39 ), which was shown to recognize only bound leptin, and also against the soluble form of the leptin receptor. 47 The`gold standard' for measuring free hormone concentrations is equilibrium dialysis but there is, as yet, no published information of this type for leptin. We have attempted to develop a miniaturized equilibrium dialysis procedure for this purpose but this proved unreliable, probably as a consequence of non-speci®c binding interferences.
Leptin binding is stable in samples stored at 3 20 Ê C for prolonged periods 30, 37 but serum/ plasma differences have been reported. 27 Binding has, however, been shown to dissociate at 22 Ê C and above 24 and most separation procedures used to measure leptin binding are conducted at 4 Ê C. The signi®cance of this temperaturedependence requires further investigation in relation to the physiological role, if any, of the binding component.
CLINICAL UTILITY
Although there is increasing evidence that leptin is a powerful regulator of metabolism and neuroendocrine function, 48 the diagnostic utility of leptin and leptin binding measurements is currently restricted to identi®cation of cases of gross obesity due to mutations in either the ob or ob-receptor gene. Despite a frantic world-wide ®shing exercise it is now clear that such mutations are extremely rare, with only three families (all consanguineous) being identi®ed to date (see Table 1 ). In these cases there is a marked discrepancy between fat mass and the circulating leptin concentration whereas, in most other pathological situations, circulating leptin concentrations relate to fat mass. A number of researchers, however, have claimed subtle leptin abnormalities in conditions such as diabetes, 49 thyroid disease, 50 Cushing's syndrome 51 and polycystic ovarian disease. 52 We have shown, in carefully controlled studies, that in cases of gross obesity associated with Prader±Willi syndrome 53 and in patients with weight-losing cancer, 54 circulating leptin concentrations are appropriate for body mass. In patients with anorexia nervosa and bulimia nervosa leptin concentrations again relate to body composition. 55 In weight-losing syndromes, circulating leptin concentrations can be as low as those found in patients with congenital leptin de®ciency. Despite this, appetite is not stimulated, suggesting that other factors must override the low leptin signal in these situations. Leptin, although undoubtedly of major importance, is not the only hormone involved in the control of appetite and energy balance. In addition to the known effects of insulin and neuropeptides (see Fig. 3 ), many`new' molecules with an important role in energy homeostasis have recently been identi®ed. 14 It is hoped that the relative contributions and interactions of these factors will become clearer over the next few years.
The one relatively common clinical condition in which a signi®cantly elevated serum leptin concentration occurs without an increase in body mass is chronic renal failure, probably as a result of decreased renal clearance. 56 Leptin is produced by the placenta as well as the adipocyte, and circulating concentrations of both total and free leptin increase during pregnancy. 20, 47, 57 Furthermore, trophoblastic tissue can also produce leptin; in patients with hydatidiform mole, rising circulating leptin concentrations have been shown to be related to disease progression. 58 During puberty, subtle changes in leptin-binding activity have recently been described which may be related to changes in leptin receptor expression, 29 suggesting that measurement of leptin binding may be of value in the investigation of abnormalities during puberty.
CONCLUSIONS
There are many areas of medicine in which the application of scienti®c discoveries takes a long time to be realized. The discovery of prolactin and inhibin are endocrine examples ± the measurement of serum prolactin appeared to have little diagnostic signi®cance until prolactinomas were discovered and the diagnostic role for inhibin is just beginning to become clear many years after such a substance was hypothesized. An incredible amount of research has been conducted on leptin since its discovery just 6 years ago and clinical biochemists are now able to build on this information. We can help identify and establish secure methodologies for measuring leptin, determine the importance of its binding to circulating macromolecules, and apply total, bound and free leptin measurements to the clinical situation. It may still be that the diagnostic potential of such measurements is limited to the identi®cation of rarities, but I believe it is more likely that a much wider clinical role will emerge over the next few years. 
APPENDIX
MANUFACTURERS AND SUPPLIERS
